The Board of Directors of Vigmed proposes a fully underwritten rights issue
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, HONG KONG, SOUTH AFRICA, SINGAPORE, NEW ZEALAND OR JAPAN (OTHER THAN IN RELATION TO EXISTING SHAREHOLDERS AND TO SUCH EXTENT THAT IS GIVEN UNDER THE PROVISIONS REGARDING THE SO CALLED “SMALL NUMBER PRIVATE PLACEMENT” UNDER ARTICLE 2, PARAGRAPH 3, ITEM 2, SUB-ITEM (HA) OF THE FINANCIAL INSTRUMENTS AND EXCHANGE ACT OF JAPAN) OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.
For more information regarding the rights issue, please refer to Vigmed Holding AB’s website:
For more information
CEO Henrik Olsen, tel. +46 763-497 364
Board member Georg Heftberger, tel. +43 664 884 106 83
This information was submitted for publication, through the agency of the contact persons set out above, at 08:00 CET on 21 June 2017.
Publication or distribution of this press release in certain jurisdictions may be restricted by law and persons in those jurisdictions where this press release is published or distributed should inform themselves about and observe such restrictions.
This press release may not be released, published or distributed, directly or indirectly, in or into the United States, Canada, Australia, Hong Kong, South Africa, Singapore, New Zealand or Japan (other than in relation to existing shareholders and to such extent that is given under the provisions regarding the so called “small number private placement” under Article 2, Paragraph 3, Item 2, Sub-item (ha) of the Financial Instruments and Exchange Act of Japan) or any other country where such action is wholly or partially subject to legal restrictions. The information in this press release may not be forwarded, reproduced or disclosed in ways that conflict with such restrictions. Omission to follow this instruction may result in violation of the United States Securities Act of 1933 ("Securities Act"), as amended, or applicable laws of other jurisdictions.
This press release does not constitute an invitation or offer to acquire, subscribe for or otherwise trade in subscription rights, interim shares or new shares in Vigmed Holding AB (publ). An invitation for interested persons to subscribe for shares in Vigmed Holding AB (publ) will only be made through the prospectus that Vigmed Holding AB (publ) intends to publish in connection with the Issue.
Neither the subscription rights, interim shares or new shares will be registered under the Securities Act, or under the securities laws of any state of the United States or any province in Canada and may not be offered or sold in the United States or Canada or to a resident there or on behalf of such persons other than in such exceptional cases that do not require registration under the Securities Act or any provincial act in Canada.
In case of differences between the Swedish and English press releases, the Swedish press release shall prevail.
Vigmed is a Swedish medical technology company whose mission is to eliminate needlestick injuries and the associated risk of cross infections with blood-borne infectious diseases by offering the market unique needle-protected products. Vigmed is headquartered in Helsingborg, Sweden. Vigmed’s share is traded on NASDAQ OMX First North in Stockholm (ticker VIG). Remium Nordic AB is the Company’s Certified Advisor.Additional information about the company can be found on Vigmed’s website: www.vigmed.com/investor